Σύγκριση μεθόδων

	AIMS: Κλίμακα Αξιολόγησης Ακούσιων Κινήσεων	Κλίμακα Βαθμολόγησης Hunt και Hess	MDS-UPDRS
Πεδίο	Νευρολογία	Νευρολογία	Νευρολογία
Οικογένεια	Process / pipeline	Process / pipeline	Process / pipeline
Έτος προέλευσης	1976	1968	2008
Δημιουργός	National Institute of Mental Health	William E. Hunt and Robert M. Hess	Christopher G. Goetz and Movement Disorder Society
Τύπος	Clinician-rated observation	Clinician-rated	Clinician-rated
Θεμελιώδης πηγή	National Institute of Mental Health (1976). Abnormal Involuntary Movement Scale (AIMS). In: Rockland, L. H., Schooler, N. R., & Levine, J. (Eds.), Drug Treatment of Mental Disorders. New York: Raven Press.	Hunt, W. E., Hess, R. M. (1968). Surgical risk as related to time of intervention in the repair of intracranial aneurysms. Journal of Neurosurgery, 28(1), 14-20.	Goetz, C. G., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129-2170.
Εναλλακτικές ονομασίες	AIMS	Hunt-Hess Grade	UPDRS
Συναφείς	3	4	5
Σύνοψη	The Abnormal Involuntary Movement Scale (AIMS) is the standard clinical rating scale for assessing tardive dyskinesia, a iatrogenic movement disorder resulting from chronic antipsychotic medication exposure. Developed by the National Institute of Mental Health in 1976, the 12-item scale systematically measures involuntary movements across facial, oral, limb, and trunk regions. The AIMS is mandatory screening tool for patients on long-term antipsychotic therapy and essential for monitoring antipsychotic-associated movement complications.	The Hunt and Hess Scale is the most widely used clinical grading system for assessing severity and prognosis in subarachnoid hemorrhage (SAH) caused by ruptured intracranial aneurysm. Developed by neurosurgeons William Hunt and Robert Hess in 1968, the five-point ordinal scale measures level of consciousness and presence of focal neurological deficits. Hunt-Hess grade at admission is the single strongest predictor of 30-day mortality and functional outcome and guides urgency of neurosurgical intervention.	The MDS-UPDRS is the gold-standard clinician-administered rating scale for assessing motor and non-motor manifestations of Parkinson's disease. Developed by the Movement Disorder Society in 2008 to enhance the original UPDRS, it measures disease severity across daily living, motor function, and treatment complications. Used globally in clinical trials, longitudinal cohort studies, and routine neurological practice.